Drug Profile

CTCE 0214

Alternative Names: CTCE-0214

Latest Information Update: 16 Jul 2016

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chemokine Therapeutics
Class Chemokines
Mechanism of Action Chemokine CXCL12 stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Stem cell mobilisation

Most Recent Events

16 Jul 2016 No recent reports of development identified for phase-I development in Stem-cell-mobilisation in USA (SC)
28 Dec 2006 Clinical data added to the adverse events and Haematological Disorders pharmacodynamics sections
21 Jun 2006 Chemokine Therapeutics has entered into an agreement with Fred Hutchinson Cancer Research Center to investigate CTCE 0214 in repopulating blood stem cells

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com